NanoString will initially draw $60 million at close, which will net it approximately $8 million after repaying its existing debt with the investment firm.
Using samples from different points in patients' treatment, researchers employed a variety of tools, including NanoString's GeoMx DSP, to explore potential response markers.
The new additions reflect data published this summer in the TAILORx trial, which speak to the chemopredictive ability of Genomic Health's Oncotype DX.
The blood-based test, called Melaseq, measures 38 circulating microRNAs that regulate processes that melanoma cells undergo as they become malignant.
The company is marketing the panel, which runs on NanoString Technologies' nCounter System, to chemical and cosmetics firms as a replacement for animal models.
CareDx led the Index for the month — the firm's shares rose 81 percent on the strength of its second quarter earnings report.
The decline was in line with what the company preliminarily reported last month, reflecting much lower collaboration revenues than in the prior year period.
The company hopes to use proceeds from the stock offering to support the commercial launch of its Digital Spatial Profiling platform next year.
The company will offer 4 million shares of common stock at a price of $12.50 per share, with an option for underwriters to purchase up to an additional 600,000 shares.
NanoString Technologies hopes to use proceeds from the stock offering to support the commercial launch of its Digital Spatial Profiling platform next year.
This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.
The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.
Researchers find that people's genetics influence their success at university, but that it is not the only factor.
In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.